
Gb Sciences, recently announced positive results from a study of its cannabinoid-containing mixtures as a potential treatment for cytokine release syndrome (CRS). With the high rate of transmission of the Omicron variant in multiple countries, Gb Sciences team are working to move quickly through the development stages for this novel CRS therapy.







